Cancer Clinical Trials

When the way forward isn’t clear…

Maybe a clinical trial is right for you.

If you or a loved one has cancer and the current treatment option isn’t working, a clinical trial might be right for you. Clinical trials offer the latest therapy to improve on the standard of care and to test how new medical approaches work when other methods have failed. Clinical treatments have resulted in new treatments and prevention options for cancer care.

Participation in a cancer clinical trial also offers more interactive, precise and personalized care for you. Your treatment team is broader, coming from a range of disciplines. This allows more individualized attention to your care. A Phase I clinical trial can also allow you to stay closer to your home setting without having to travel to another destination.

If you are interested in learning more about a clinical trial, complete the form below or call (864) 920-2523. (This number is answered Monday through Friday, 8:30 a.m. to 5 p.m.  Please leave a voice message after business hours and your call will be returned within two business days.)

View below all of our active clinical trials.

Request Information on Clinical Trials

Someone will contact you within two business days.

How May We Help You?

Contact us: (864) 920-2523

Monday through Friday, 8:30 a.m. to 5 p.m.
or leave a message after business hours if you need active treatment for cancer. These trials do not pay you for participation.

Learn more about Clinical Trials

Learn more about clinical trials supported by National Cancer Institute (NCI) in this brief video.

Clinical Trials Available

Current Clinical Trials

Disease SiteStudyLocation
Disease Site: Lymphoma

CTSU EA4151   View on ClinicalTrials.gov
A Randomized Phase III Trial of Consolidation with Autologous Hematopoietic Cell Transplantation Followed by Maintenance Rituximab vs. Maintenance Rituximab Alone for Patients with Mantle Cell Lymphoma In Minimal Residual Disease-Negative First Complete Remission

OP Cancer Institute Research
864-241-6251
Disease Site: Prostate

Suzhou Kintor Pharmaceutical, Inc. GT0918-US-1002   View on ClinicalTrials.gov
An Extended/Phase 2, Multi-Center, Randomized, Open-Label Study to Evaluate the Safety and Tolerability of Proxalutamide (GT0918) in Subjects with Metastatic Castrate Resistant Prostate Cancer (mCRPC) who Failed Either Abiraterone or Enzalutamide

OP Cancer Institute Research
864-241-6251
Disease Site: Renal

Alliance A031704   View on ClinicalTrials.gov
PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab Vs. VEGF TKI Cabozantinib with Nivolumab: A Phase III Trial in Metastatic Untreated REnal Cell CancEr[PDIGREE]

OP Cancer Institute Research
864-241-6251
Disease Site: AML

USO 18168/AbbVie M19-072   View on ClinicalTrials.gov
A Phase 3b, Single-Arm, Multicenter Open-Label Study of Venetoclax in Combination with Azacitidine or Decitabine in an Outpatient Setting in AML Patients Ineligible for Intensive Chemotherapy

OP Cancer Institute Research
864-241-6251
Disease Site: Lymphoma

USO 18104   View on ClinicalTrials.gov
A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) in the Outpatient Setting (017007)

OP Cancer Institute Research
864-241-6251
Disease Site: Germ Cell Tumors

CTSU COG AGCT 1531   View on ClinicalTrials.gov
A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients With Germ Cell Tumors

OP Cancer Institute Research
864-241-6251
Disease Site: Renal

SWOG S1500   View on ClinicalTrials.gov
A Randomized, Phase II Efficacy Assessment of Multiple MET Kinase Inhibitors (Cabozantinib [NSC #761968], Crizotinib [NSC #749005], Savolitinib [NSC #785348], and Sunitinib [NSC #736511]) in Metastatic Papillary Renal Carcinoma (PAPMET)

OP Cancer Institute Research
864-241-6251
Disease Site: Pancreatic

RTOG 0848   View on ClinicalTrials.gov
A PHASE II-R and A PHASE III TRIAL EVALUATING BOTH *ERLOTINIB (PH II-R) AND CHEMORADIATION (PH III) AS ADJUVANT TREATMENT FOR PATIENTS WITH RESECTED HEAD OF PANCREAS ADENOCARCINOMA

OP Cancer Institute Research
864-241-6251
Disease Site: Breast

SWOG S1706   View on ClinicalTrials.gov
A Phase II Randomized Trial of Olaparib (NSC-747856) Administered Concurrently with Radiotherapy versus Radiotherapy Alone for Inflammatory Breast Cancer

OP Cancer Institute Research
864-241-6251
Disease Site: Anal

CTSU EA2165   View on ClinicalTrials.gov
A Randomized Phase II Study of Nivolumab After Combined Modality Therapy (CMT) in High Risk Anal Cancer

OP Cancer Institute Research
864-241-6251